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Background: Several observational studies on hypertensive patients have shown a gap between therapeutic
targets recommended in guidelines and those achieved in daily practice. The ESCAPE trial aimed to determine
whether a multifaceted intervention focused on general practitioners (GPs), could increase significantly the
proportion of hypertensive patients at high risk in primary prevention who achieved all their recommended
therapeutic targets.
Methods: A pragmatic, cluster randomized trial involving 257 GPs randomized by region. The GPs in the
intervention group had a one-day training session and were given an electronic blood pressure measurement
device and a short recommendation leaflet. Along with usual follow-up, they focused one consultation on
hypertension and other cardiovascular risk factors every six months for two years. They also received feedback at
baseline and at one year on their patients’ clinical and biological parameters. Main outcome measures were change
in the proportion of patients achieving all their therapeutic targets and each individual therapeutic target at two
years, and quality of life.
Results: 1,832 high-risk hypertensive patients were included. After two years, the proportion of patients achieving
all their therapeutic targets increased significantly in both groups, but significantly more in the intervention group:
OR (odds-ratio) 1.89, (95% confidence interval (CI) 1.09 to 3.27, P = 0.02). Significantly more patients achieved their
blood pressure targets in the intervention group than in the usual care group: OR 2.03 (95% CI 1.44 to 2.88,
P < 0.0001). Systolic and diastolic blood pressures decreased significantly more in the intervention group than in the
usual care group, by 4.8 mmHg and 1.9 mmHg, respectively (P < 0.0001 for both). There were no significant
difference changes in physical and mental quality of life between groups.
Conclusion: An easy-to-perform, multifaceted intervention targeting only GPs increased significantly the proportion
of high-risk hypertensive patients in primary prevention achieving their recommended therapeutic targets.
Trial registration: This trial was registered with ClinicalTrials.gov, number NCT00348855
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French [1,2] and European [3] guidelines for the primary
prevention of cardiovascular complications in patients
with hypertension are mainly based on blood pressure
targets that should be achieved along with other risk-
reducing strategies. As these patients are at an increased
cardiovascular risk, the recommendations also set tar-
gets for low-density lipoprotein cholesterol (LDL), smok-
ing cessation, and, in patients with type-2 diabetes,
HbA1c and low-dose aspirin treatment [2].
In France, more than ten million patients are treated for
hypertension [4]. Slightly more than three-quarters of
these are for primary prevention [5] and 92% are followed
exclusively by general practitioners (GPs) [4]. Recent stud-
ies in the general population [6,7] have reported that be-
tween 50% and 76% of treated hypertensive patients had
uncontrolled hypertension, that is, ≥ 140/90 mmHg. For
those followed by GPs, the last published rate was 58%,
showing a gap between recommendations and practice
[8]. Furthermore, the more risk factors that hypertensive
patients receiving primary prevention treatment have, the
worse these risk factors are controlled [5,9,10].
A common explanation for the gap between guidelines
and practice is patients’ lack of adherence, but another key
reason is therapeutic inertia, that is, the failure of health
care providers to start or increase treatment when the
therapeutic targets are not met [11,12]. Targeting an inter-
vention to the healthcare providers is one means of ensur-
ing that patients receive optimal therapeutic benefit by
reducing therapeutic inertia. Randomized trials under-
taken in this area have evaluated various types of interven-
tions (mono- or multifaceted) with patients, their families,
physicians, physician assistants, nurses [13], pharmacists
and health care organizations, either separately or in dif-
ferent combinations. A systematic review of these trials
reported a non-significant reduction of 0.4 mmHg (95%
confidence interval (CI) = −1.1 to 0.2) in systolic blood
pressure (SBP) and 0.4 mmHg (95% CI = −1.1 to 0.3) in
diastolic blood pressure (DBP) in patients followed by
healthcare providers who were randomized to the inter-
vention groups [14].
The few randomized clinical trials that measured the
impact of interventions targeting GPs, were heteroge-
neous in their modalities and in most cases; other health
professionals (for example, nurses, assistants) also re-
ceived the intervention. These interventions did not sig-
nificantly increase the proportion of patients achieving
recommended therapeutic targets or a clinically relevant
reduction in blood pressure [12-18].
The ESCAPE trial aimed to determine whether a multi-
faceted intervention focused exclusively on GPs could in-
crease significantly the proportion of hypertensive patients
at high risk in primary prevention who achieved their
recommended therapeutic targets.Methods
ESCAPE was a two-year pragmatic, randomized cluster
controlled trial. In fact, a traditional randomized trial in
which the patients would have been randomized was
impossible because the intervention was aimed at doc-
tors, not patients. The Institutional Review Board of
Versailles approved the study in May 2006. All patients
gave written informed consent for their data to be used
for this trial.
Participants
The physicians were all GPs and were members of the
French National College of Teachers in General Prac-
tice (CNGE). Firstly, all the 33 French regional colleges
belonging to the CNGE were invited to participate in ‘a
randomized trial with hypertensive patients’. Twenty-
three of these colleges agreed to participate. Eight
hundred and seventy-seven GPs, members of these 23
colleges, were contacted by each regional research
leader by telephone and/or Email, or during a usual
meeting, and 335 agreed to participate.
Randomization
One of our aims was to reduce the contamination bias,
which corresponds to the appropriation of the interven-
tion group methods by the control group, following con-
tacts between investigators. To minimize contamination
bias as much as possible, the regional colleges were ran-
domized rather than the GPs themselves. We achieved
therefore a sort of geographical and functional isolation
of the clusters. Thus, all participating GPs from a given
regional college were randomized to the same study
group. Randomization was conducted after recruiting
GPs [19] through the use of a computer program pro-
vided by the Claude Bernard University Department of
Clinical Pharmacology in Lyon that was also in charge of
the data management. Of the 23 colleges which agreed
to participate in the trial, 11 were allocated to the usual
care group and 12 to the intervention group.
Patients’ inclusion criteria
To be included, patients had to be aged between 45 and
75 years, to be treated for hypertension for at least six
months, not to have any known clinical signs or history
of cardiovascular disease, and to have at least two of the
following cardiovascular risk factors [1]:
 Age ≥ 50 years for men and ≥ 60 years for women.
 Family history of myocardial infarction or sudden
early death (at ≤ 55 years for a first-degree male
relative or ≤ 65 years for a first-degree female relative)
or stroke at ≤ 45 years for a first-degree relative.
 Active smoker or having quit smoking < three
years ago.
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glycemia ≥ 7 mmol/L at two occurrences or use of
an anti-diabetic drug).
 LDL ≥ 4.14 mmol/L or use of lipid-lowering drug.
 High-density lipoprotein cholesterol (HDL) ≤
1.04 mmol/L (one risk factor was subtracted if
HDL ≥ 1.55 mmol/L).
 Known left ventricular hypertrophy (diagnosed by
ultrasound or electrocardiography).
 Urinary excretion of albumin ≥ 20 mg/L.
GPs were asked to include the first eligible patients they
saw over a week, with a minimum of seven patients.
Exclusion criteria
Patients were not eligible if they had type-1 diabetes,
were unable to participate in a two-year trial, had a ser-
ious life-threatening disease with a poor short-term
prognosis, or could not understand French.
Intervention
In the intervention group, GPs attended a one-day
training seminar about therapeutic targets and strat-
egies to achieve them as recommended by the French
guidelines [1,2]. Using a common teaching kit, four
trained university GP lecturers delivered the stan-
dardized regional training seminars between September
and December 2006. The GPs in this group were given
a validated electronic blood pressure measurement
device (Spengler TB101, Spengler SAS, Antony, France)
to improve the accuracy of blood pressure measure-
ments. They were also given a six-page leaflet that sum-
marized targets and therapeutic strategies recommended
in the guidelines which they were asked to keep on their
office desk.
Every six months during the two-year trial, the GPs
were asked to dedicate one routine follow-up consult-
ation to optimize (if needed and possible) the treatment
of the patients who had not achieved their individual
targets. The GPs were also asked to discuss systematic-
ally the patient’s lifestyle (diet and exercise), adherence
to drug treatment and to give advice on quitting smok-
ing if the patient smoked. Advice for lifestyle was not
standardized. Lastly, at the end of recruitment and after
the 12-month consultation, GPs in the intervention
group received feedback on their patients’ clinical and
biological data.
The GPs randomized in the usual care group at-
tended a 90-minute meeting to learn about the inclu-
sion and exclusion criteria and how to complete the
study case report forms. They were not told about the
study aims, the nature of the intervention or any end-
points, so that they would continue to treat their pa-
tients in their usual way.Patient follow-up
At baseline, and every six months for two years along
with usual follow-up, the GPs in both groups collected
patients’ clinical and biological data. Prescriptions of
drugs for hypertension and metabolic treatment were
reported at baseline and 24 months. At inclusion, 12-
months and 24-months, patients of both groups were
given a sealed envelope containing five short question-
naires on quality of life (SF-8), adherence [20], diet, exer-
cise, and smoking habits to be completed at home and
sent directly to the data treatment center in a pre-paid
envelope. The patients could therefore complete the
questionnaires without being influenced by their doctor,
hence by the group to which they belonged.
Endpoints
The primary endpoint was the change in the propor-
tion of patients achieving all of their therapeutic tar-
gets at two years. Three therapeutic targets were
defined for patients without type-2 diabetes: BP ≤ 140/
90 mmHg, LDL ≤ 3.36 mmol/l, and no smoking [1].
Five therapeutic targets were defined for patients with
type-2 diabetes: BP ≤ 130/80 mmHg, LDL ≤ 2.59 mmol/l,
HbA1c ≤ 7%, no smoking, and a prescription for low-dose
aspirin [2].
The secondary endpoints were the change in the
proportion of patients achieving each of their individ-
ual targets and the values for BP, LDL, and HbA1c.
Other secondary endpoints were the variation in the
Framingham-Anderson score for coronary risk [21], the
occurrence of the first clinical cardiovascular event
(validated by a committee blinded to randomization),
change in antihypertensive drug prescriptions, and
quality of life.
Sample size calculation
The sample size was calculated following the method of
Hayes and Bennett [22], accounting for the cluster de-
sign of the trial. This method uses the between-cluster
coefficient of variation k, which was estimated to be 0.27
at the end of the inclusion period. For the primary end-
point in the whole included population, it was calculated
that 23 clusters including 70 patients each, would be
needed to give the trial a 90% power to detect success
rate of 10.5% in the usual care group and 19.5% in the
intervention group, assuming a conservative value 0.3
for k, and an alpha risk of 0.05. Assuming that 10% of
the data would not be available at the end of the trial, it
was calculated that 885 patients were necessary in each
study group.
Statistical analyses
The intervention and usual care groups were compared
at baseline using the Kruskal-Wallis test for continuous
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the chi-squared test for categorical variables with more
than two categories.
Three-level hierarchical generalized linear models
were used to analyze the evolution of the criteria over
time, with practices and patients included as random
effects. The model also included a fixed group effect, a
linear time effect, and a differential effect of the inter-
vention group versus the usual care group over time
(interaction), which was the effect of interest. Missing
outcomes, at a given time point, were estimated with
their unbiased linear predictor. Another fixed-effect
model was used to estimate directly the evolution of
the criteria over time in the two groups (with 95% con-
fidence intervals). Continuous and binary variables
were modeled using an identity function and a logit
link function, respectively. The results are presented as
odds-ratios (OR) with 95% CI, and reported at the pa-
tient level.
A post hoc sensitivity analysis restricted to centers
that used only an automatic blood pressure measure-
ment device was performed to evaluate the extent to
which the use of conventional blood pressure meas-
urement in the usual care group might have affected
the results. We performed another post hoc analysis
of blood pressure changes that included all the patient
population and was adjusted on baseline blood pressure.
The data preparation and descriptive statistics were
performed using SAS (Windows, v. 9.1, SAS Institute
Inc., Cary, NC, USA.). Modeling was performed using
the generalized linear latent and mixed models
(gllamm) function of STATA (Windows, v. 9, Stata-
Corp. 2005. /Stata Statistical Software: Release 9/. Col-
lege Station, TX: StataCorp LP).Figure 1 Flow of practices and patients through study.Results
Recruitment
Eleven colleges (173 GPs) were randomized to the usual
care group and 12 (162 GPs) to the intervention group.
Attendance at the one-day training in the intervention
group or the 90 minute-meeting in the usual care group
was mandatory for GPs to include patients. One hun-
dred and forty-five GPs (90%) in the intervention group
attended the one-day training, of which 126 (87%)
recruited at least one patient in the trial. One hundred
and forty-four GPs (83%) in the usual care group
attended the 90 minute-meeting, of which 131 (90%) in-
cluded at least one patient (Figure 1). The characteristics
of the active GPs were similar in both groups in terms of
gender, age, type and duration of practice (data not
shown). The mean number of patients recruited per
GP was 7.1 (minimum = 1, maximum = 16). Between
November 2006 and July 2007, 1,832 patients were in-
cluded in the trial, 927 in the usual care group and 905
in the intervention group. On average, they were 62 (SD
7.8) years old, and the sex ratio of men to women was
2:1. All patients were in primary prevention, had been
treated for hypertension for an average of 10.9 years (SD
8.1), and 71% had more than two other cardiovascular
risk factors associated with hypertension. The average
body mass index was 30.5 kg/m2. The average diabetes
duration of the 1,047 patients with type-2 diabetes was
7.5 years (SD 6.5).
At baseline (Table 1), patient characteristics were com-
parable in both groups, except for SBP and DBP, which
were significantly higher in the intervention group by
7 mmHg and 3 mmHg, respectively (P < 0.001). In
addition, significantly fewer diabetic patients had a pre-
scription for aspirin in the usual care group compared
Table 1 Baseline characteristics of patients
Characteristic Intervention (n = 905) Usual care (n = 927)
Male, n (%) 575 (63.5) 589 (63.5)
Mean age, years (SD) 62.1 (7.9) 62.4 (7.7)
Height, cm (SD) 166.9 (9.3) 167.4 (9.1)
Weight, kg (SD) 85.8 (16.5) 85.6 (15.9)
Body Mass Index, kg/m2 (SD) 30.7 (5.2) 30.5 (5.0)
Men with waist≥ 102 cm, n (%) 358 (62.8) 385 (66.3)
Women with waist≥ 88 cm, n (%) 279 (85.6) 278 (85.3)
Mean systolic blood pressure, mmHg (SD)a 145.9 (15.3) 138.7 (13.5)
Mean diastolic blood pressure, mmHg (SD)a 83.7 (11.7) 80.6 (9.2)
Heart rate, beats/min (SD) 71.4 (10.9) 71.6 (10.4)
Total cholesterol, mmol/l (SD) 5.27 (1.15) 5.29 (1.14)
HDL, mmol/L (SD) 1.30 (0.35) 1.32 (0.37)
LDL, mmol/L (SD) 3.19 (1.02) 3.21 (1.04)
Triglyceride, mmol/L (SD) 1.84 (1.19) 1.78 (1.00)
Creatininemia μmol/L (SD) 86.2 (29.9) 85.4 (25.5)
MDRD-estimated glomerular filtration rate, ml/min (SD) 79.6 (19.6) 80.8 (20.2)
Fasting glycemia, mmol/l (SD) 6.88 (1.94) 6.77 (1.94)
Left ventricular hypertrophy, n (%) 150 (16.6) 184 (19.9)
Family history of early cardiovascular event, n (%) 225 (24.9) 253 (27.3)
Albuminuria ≥ 20 mg/L, n (%) 186 (22.3) 154 (18.1)
Mean years since diagnosis of hypertension (SD) 10.5 (7.8) 11.2 (8.3)
Smoker status
Current n (%) 193 (21.3) 217 (23.4)
Past smoker < three years n (%) 72 (8.0) 94 (10.2)
Non-smoker n (%) 640 (70.7) 615 (66.4)
Number of antihypertensive drugs, n (SD) 2.16 (1.04) 2.18 (1.04)
Type-2 diabetes, n (%) 527 (58.2) 521 (56.2)
Mean years since diagnosis of type-2 diabetes, (SD) 6.9 (6.1) 7.8 (6.9)
HbA1c, % (SD) 7.0 (1.1) 7.0 (1.2)
Cardiovascular risk factors, n (%)
Men > 50 or women > 60 years old 779 (86.1) 802 (86.6)
Current smoker or past smoker < three years 265 (29.3) 311 (33.6)
LDL ≥ 4.14 mmol/L or treatment 692 (76.5) 686 (74.0)
HDL≤ 1.04 mmol/L 189 (20.9) 190 (20.6)
Number of cardiovascular risk factors, n (%)
≤ 2 259 (28.6) 264 (28.5)
3 319 (35.2) 315 (34.0)
4 222 (24.5) 247 (26.6)
≥ 5 105 (11.6) 101 (10.8)
Ten-year Framingham-Anderson risk score, (%) 17.5 17.0
Achieved all therapeutic targets (3 or 5), n/N (%)a 56/900 (6.2) 94/923 (10.2)
Achieved blood pressure target, n (%)a 207 (23.0) 392 (42.6)
Achieved LDL target, n (%) 370 (41.1) 395 (43.4)
No smoking, n (%) 712 (78.7) 709 (76.6)
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Table 1 Baseline characteristics of patients (Continued)
Patients with diabetes
Achieved HbA1c target n/N (%) 312/527 (60.1) 316/521 (61.7)
Low-dose aspirin (yes) n/N (%)a 225/527 (42.7) 140/521 (26.9)
astatistically significantly different between groups (P < 0.001).
MDRD, modified diet in renal disease; SD, standard deviation.
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0.001). Finally, the percentage of patients achieving all
of their therapeutic targets at baseline was signifi-
cantly lower in the intervention group: 6.2% versus
10.2% (P = 0.005).Primary endpoint
Due to missing values at every time point, the primary
endpoint could not be modeled for six patients; there-
fore, the analysis for the primary endpoint was based
on 1,826 patients. Over two years of follow-up, the pro-
portion of patients achieving all of their therapeutic targets
increased in both groups, but the increase was signifi-
cantly higher in the intervention group: OR 1.89, 95% CI
1.09 to 3.27, P = 0.024 (Table 2). Similar trends were ob-
served in patients with and without type-2 diabetes, but
did not achieve statistical significance.Secondary endpoints
Individual therapeutic targets
The proportion of patients achieving their BP targets did
not change significantly in the usual care group. However,
significantly more patients in the intervention group
achieved their BP targets at two years. The difference be-
tween the two groups was significant: OR 2.03, 95% CI
1.44 to 2.88, P < 0.001 (Table 3). The proportion of pa-
tients achieving their targets for LDL and quitting smok-
ing increased in both groups, with no significant
difference between the groups. There was no change in
the proportion of patients with HbA1c ≤ 7% in either
group in the type-2 diabetes sub-population.Table 2 Primary outcome: changes within groups and differe
proportion of patients achieving all their therapeutic targets
Endpoint Group M0 n/N (%) M24 n/N (%)
All patients (3 or 5 targets) Intervention 56/900 (6.2) 110/860 (12.8)
Usual care 94/923 (10.2) 118/860 (13.7)
Hypertension + T2D (5 targets) Intervention 7/527 (1.3) 24/526 (4.6)
Usual care 9/520 (1.7) 14/513 (2.7)
Hypertension (3 targets) Intervention 49/373 (13.1) 86/334 (25.8)
Usual care 85/403 (21.1) 104/347 (29.0)
CI, confidence interval; M0, month 0; M24, month 24; T2D, type-2 diabetes; OR, oddThe proportion of patients with type-2 diabetes who
received a prescription of low-dose aspirin increased in
both groups, the increase in the intervention group be-
ing significantly higher than in the usual care group: OR
2.28, 95% CI 1.27 to 4.09, P = 0.006.Other endpoints
The changes in the main risk factor parameters are sum-
marized in Table 4. SBP was reduced by 1.2 mmHg in
the usual care group and by 6.0 mmHg in the inter-
vention group. The 4.8 mmHg absolute difference be-
tween the two groups was statistically significant, in
favor of the intervention group (P < 0.001). Similarly, for
DBP, the absolute difference between the groups at the
end of the trial was 1.9 mmHg, statistically significant in
favor of the intervention group (P < 0.002).
At baseline, the Framingham-Anderson scores were
comparable in the two groups. In absolute values, this
score decreased by 1.2% in the usual care group and
by 2.2% in the intervention group. The difference be-
tween the two groups was statistically significant in
favor of the intervention group (P < 0.001).Sensitivity analysis of blood pressure
Restricting the analysis to centers that measured blood
pressure with an automatic device (900 patients in the
intervention group and 248 in the usual care group) gave
similar results, with a significant difference in favor of the
intervention group for the change in systolic (3.5 mmHg,
P = 0.001) and diastolic blood pressure (1.3 mmHg,
P = 0.045) over time.nces between groups at month 24 (M24) in the
OR (95% CI) for within
group comparison
P OR (95% CI) for between
group comparison
P-value
3.23 (2.12 to 4.94) < 0.001 1.89 (1.09 to 3.27) 0.024
1.71 (1.19 to 2.47) 0.004
3.90 (1.60 to 9.52) 0.003 2.36 (0.68 to 8.18) 0.175
1.65 (0.69 to 3.98) 0.262
3.12 (1.94 to 5.03) < 0.001 1.63 (0.99 to 3.01) 0.120
1.91 (1.27 to 2.88) 0.002
s-ratio.
Table 3 Within group and between group differences in the percentages of patients achieving their individual
therapeutic targets
Target Group M0 n/N (%) M24 n/N (%) OR (95% CI) within groups P-value OR (95% CI) between groups P-value
Blood pressurea Intervention 207/900 (23.0) 303/823 (36.8) 2.55 (1.96 to 3.30) < 0.001 2.03 (1.44 to 2.88) < 0.001
Usual care 392/923 (42.6) 382/825 (46.3) 1.25 (0.99 to 1.58) 0.060
LDL cholesterolb Intervention 370/884 (41.9) 458/793 (57.8) 2.65 (2.05 to 3.41) < 0.001 1.25 (0.88 to 1.78) 0.205
Usual care 395/910 (43.4) 435/778 (55.9) 2.11 (1.65 to 2.71) < 0.001
No smoking Intervention 712/905 (78.7) 664/804 (82.6) 3.75 (1.92 to 7.30) < 0.001 0.81 (0.41 to 1.60) 0.550
Usual care 709/926 (76.6) 659/808 (81.6) 2.98 (1.81 to 4.93) < 0.001
HbA1cc Intervention 312/519 (60.1) 275/472 (58.3) 0.81 (0.58 to 1.16) 0.257 0.77 (0.47 to 1.27) 0.310
Usual care 316/512 (61.7) 279/452 (61.7) 1.06 (0.74 to 1.53) 0.747
Low-dose aspirin Intervention 225/527 (42.7) 318/527 (60.3) 5.55 (3.61 to 8.54) < 0.001 2.28 (1.27 to -4.09) 0.006
Usual care 140/521 (26.9) 179/521 (34.4) 2.43 (1.57 to 3.77) < 0.001
CI, confidence interval; M0, month 0; M24, month 24; OR, odds-ratio.
a ≤ 140/90 mmHg or ≤ 130/80 mmHg for type-2 diabetic patients.
b ≤ 3.36 mmol/l or 2.59 mmol/l for type-2 diabetic patients.
c ≤ 7%.
Table 4 Changes in the main clinical and biological parameters between month 0 and month 24








145.9 (15.3) 139.6 (14.6) −6.00 (0.46) −4.76 (< 0.001)
Usual care
(n = 927)





83.7 (11.7) 80.2 (10.4) −3.32 (0.38) −1.88 (< 0.001)
Usual care
(n = 927)
80.6 (9.2) 79.2 (8.0) −1.44 (0.38)
LDL cholesterol (mmol/L) Intervention
(n = 905)
3.18 (1.03) 2.82 (0.85) −0.31 (0.03) 0.05 (0.075)
Usual care
(n = 927)





79.6 (19.6) 80.6 (20.1) 1.52 (0.48) 2.72 (< 0.001)
Usual care
(n = 927)











85.8 (16.5) 85.5 (16.8) −0.28 (0.12) −0.12 (0.470)
Usual care
(n = 927)
85.6 (15.9) 85.4 (16.1) −0.16 (0.12)
Waist circumference (cm) Intervention
(n = 905)
105.1 (12.8) 104.9 (13.3) −0.08 (0.16) −0.24 (0.269)
Usual care
(n = 927)
105.1 (13.3) 105.3 (13.8) 0.16 (0.16)
HbA1c (%) Intervention
(n = 527)
7.01 (1.12) 7.03 (1.10) 0.03 (0.04) 0.01 (0.341)
Usual care
(n = 521)
7.01 (1.23) 7.03 (1.13) 0.02 (0.04)
LDL, low-density lipoprotein; MDRD-estimated GFR, MDRD-estimated glomerular filtration rate; SD, standard deviation; SE, standard error. P-values refer to the
comparison of the changes between the intervention and usual care groups in a three-level hierarchical generalized linear model (see Statistics section).
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baseline values
We have also analyzed the blood pressure data with an ad-
justment on baseline values to assess the extent to which
the differential changes observed during follow-up were
dependent of the between-groups difference at baseline.
The results still demonstrate a significant effect of the
intervention. For SBP, time effect was significant (P =
0.018) and the intervention effect (P < 0.0001) and the
interaction between group and time were also significant
(P < 0.0001). The adjusted difference over two years of
follow-up was 4.8 mmHg. For DBP, time effect was signifi-
cant (P = 0.0003) and the intervention effect (P < 0.0001)
and the interaction between group and time were also sig-
nificant (P < 0.0001). The adjusted difference over two
years of follow-up was 1.9 mmHg.
Antihypertensive drugs
At baseline, the average number of antihypertensive drugs
per patient was similar in the two groups, 2.16 (SD 1.04)
in the intervention group and 2.18 (SD 1.04) in the usual
care group. After two years, this number increased in both
groups but increased significantly more in the intervention
group: 2.41 (SD 1.05) versus 2.29 (SD 1.06) in the usual
care group, (P = 0.020). In addition, significantly more pa-
tients in the intervention group received at least one add-
itional antihypertensive drug over the two-year study
period than in the usual care group (P = 0.009) (Table 5).
Cardiovascular events
During the study, 89 cardiovascular events were
reported, and 61 were validated using the patient records
by a committee blind to randomization. The incidence
of the first cardiovascular event was 3.0% in the inter-
vention and 3.7% in the usual care groups, (P = 0.513).
Quality of life
Changes in scores for physical and mental quality of life
were very small and not significantly different between
the two groups (Table 6).
Discussion
ESCAPE is the first interventional cluster randomized trial
targeted at GPs only, showing that an easy-to-perform
multifaceted intervention, significantly increased the pro-
portion of high-risk hypertensive patients in primaryTable 5 Number of patients with a least one change in the nu
Intervention, n = 812, n (%)
Reduction 72 (8.9)
No change 510 (62.8)
Increase 230 (28.3)prevention who achieved their recommended therapeutic
targets without adversely affecting their quality of life. This
high-risk hypertensive French population was chosen be-
cause their hypertension and other cardiovascular risks
are usually very poorly controlled [5,9,10]. The interven-
tion tested in the ESCAPE trial showed its efficacy for the
primary endpoint in the overall population, but not in the
two sub-populations with or without type-2 diabetes taken
apart - probably due to a lack of power, the results were
consistent. These results were obtained on an ambitious
primary endpoint and in spite of a significant improve-
ment in the usual care group, the well-known Hawthorne
effect [23]. The results from previous clinical trials in
which the intervention was not targeted exclusively at GPs
failed to show such an impact from the tested intervention
[15-18].
The main impact of the intervention was principally
due to the proportion of patients achieving their blood
pressure targets and the increased prescription of low-
dose aspirin for patients with type-2 diabetes. The other
components of the primary outcome also improved sig-
nificantly within each group (except for HbA1c), but
their change over time was comparable between the two
groups. In addition, the quality of life results suggest that
there was no ‘price to pay’ for a more intensive manage-
ment to reduce cardiovascular risk in terms of quality of
life. Although the study was not powered to produce sig-
nificant results in the two sub-populations, it showed
consistent effects in both subgroups.
The absolute difference in the reduction of SBP of
about 5 mmHg in the intervention group was clinically
relevant because this difference could be expected to re-
duce stroke mortality by 20%, and mortality related to
cardiac ischemic events or long-term overall cardiovas-
cular mortality by 15% [24].
In the ESCAPE trial, the percentage of patients
achieving all their therapeutic targets at baseline was
very low overall (8.2%), and even lower for patients with
type-2 diabetes (1.5%). This raises questions, not only
about the quality of care provided by the GPs regarding
the practice guidelines, but also about the accessibility
and relevance of the therapeutic targets recommended
for primary care settings.
In this trial, the choice of an intervention focused on
GPs only reflected the organization of the French health
care system. Unlike many other European countries, therember of antihypertensive drugs




Table 6 Quality of life measured using the Short-Form-8 quality of life questionnaire (SF-8) tool at month 0 and
month 24
Quality of life Group M0 M24 P M0-M24 P-value
SF-8 PCSS (SD) Intervention (n = 872) 47.1 (8.3) 46.3 (8.7) 0.01 0.823
Usual care (n = 868) 46.8 (8.6) 46.3 (8.9) 0.03
SF-8 MCSS (SD) Intervention (n = 872) 47.7 (9.4) 48.6 (9.2) 0.006 0.374
Usual care (n = 868) 47.4 (9.8) 47.8 (9.3) 0.13
M, month 0; M24, Month 24; MCSS, mental component summary score; PCSS, physical component summary score.
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tants, nutritionists or psychologists in French GPs’ offices.
In 2006, the French guidelines [2] recommended the
prescription of low-dose aspirin in primary prevention
for patients with type-2 diabetes and at least two other
cardiovascular risk factors (high-risk patients). In the fol-
lowing years, the results from several trials failed to sup-
port this recommendation [25,26]. Despite this, the
absolute increase for the prescription of low-dose aspirin
was 7.5% in the usual care group and 17.5% in the inter-
vention group.
The selection of similar groups of patients is never guar-
anteed in a cluster trial. However, in ESCAPE, 23 clusters
were randomized, and the patients were included by as
much as 257 investigators, which favored the constitution
of comparable groups. In fact, patients were very similar
regarding age, sex, weight, waist circumference, creatinine
clearance, blood lipids, and smoking.
It is likely that both the higher blood pressure and the
higher prescription of low-dose aspirin seen at baseline
in the intervention group were due to the intervention
itself. During the training seminar, prior to the inclusion
of patients, the GPs were given an electronic measure-
ment device and were asked to report the exact values
on the case report forms, which almost certainly im-
proved the accuracy of their BP measurements by redu-
cing substantially end-digit preference [27,28]. The BP
was shown to be underestimated in the usual care group
because of a much higher end-digit preference [27]. GPs
tend to round down BP results to the lower 0 mmHg or
5 mmHg values systematically because it is considered
better for the physician, as well as for the patient, to
have a lower value under treatment. In the absence of
any recommendation to report blood pressure values as
read in the usual care group, there is no reason why the
measurement bias observed in this group would change
during follow-up, and the comparison of the slopes of
the changes in blood pressure over time remains valid.
The effect of the intervention being tested as the inter-
action between time and the randomization group, the
differences observed between the two groups at baseline
could have only a small influence on the results, and this
was confirmed by the results of the analysis adjusted on
baseline values.Moreover, restricting the analysis to centers that used
the same method of blood pressure measurement gave re-
sults that still demonstrated a steeper decline in blood
pressure in the intervention than in the usual care group.
The 7/3 mmHg BP differences seen in ESCAPE are similar
to that shown in the CRAB study [28] that compared the
two blood pressure measurement methods in use in ES-
CAPE. The automatic blood-pressure device was part of
the intervention, which explains why it was not provided
to the usual care group. The only way to avoid the influ-
ence of the blood-pressure measurement device on the
baseline blood pressure measurements in the intervention
group would have been the recruitment of all the study
patients before cluster randomization, a recommended
method in cluster trials. This was not possible, however,
for practical and financial reasons. In fact, patient re-
cruitment took place over nine months. Moreover, if the
baseline measurements had been performed before ran-
domization, blood pressure would have risen spuriously at
the first post-randomization visit in the intervention
group, and the effect of the intervention would have been
confounded by the Hawthorne effect.
During the training seminar, intervention group GPs
were also reminded to prescribe low-dose aspirin to pa-
tients with type-2 diabetes. Due to the delay between
this seminar and the inclusion of the first patients, some
GPs have probably prescribed low-dose aspirin to pa-
tients with type-2 diabetes before including them into
the ESCAPE trial.
Finally, the significant increase in MDRD renal blood
flow in the intervention compared with the usual care
group can be considered as a proof of a genuine improve-
ment in cardiovascular risk management. In fact, because
this parameter was not calculated using blood pressure
values, results reflect real and not spurious changes in car-
diovascular management.
Since the ESCAPE trial began, several randomized clus-
ter trials with hypertensive patients or patients at high
cardiovascular risk have been published. What makes ES-
CAPE original is that the intervention was targeted exclu-
sively at GPs, and that it involved only hypertensive
patients at high cardiovascular risk in primary prevention.
EUROACTION [29] assessed an intervention delivered by
nurses to patients at high cardiovascular risk and their
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increase in the proportion of patients with a BP below
140/90 mmHg in the intervention group. However in
EUROACTION, the intervention, the effectors (nurses),
the people exposed to the intervention (patients and fam-
ilies) and the primary endpoint were different from those
in ESCAPE since the patients in ESCAPE had a different
profile and their family members were not directly ex-
posed to the intervention. In the SPHERE trial [30], the
intervention was complex, multifactorial, with multi-
effectors (nurses and GP university lecturers) and multi-
targets (nurses and GPs in practice). In addition, the pa-
tients included into the trial were all treated for secondary
prevention. A significant reduction in the proportion of pa-
tients hospitalized for cardiovascular events was reported,
without a significant increase in the proportion of patients
achieving their blood pressure and total cholesterol targets.
However, unlike the patients in ESCAPE, those included in
the SPHERE trial were particularly well-controlled at inclu-
sion, which led to a ceiling effect. In the COM99 trial, the
intervention, which was targeted at hospital physicians and
GPs, aimed to improve patients’ treatment adherence, their
blood pressure control and to reduce the risk of cardiovas-
cular events [31]. The physicians applied the intervention
(motivational interviewing techniques) to patients with
uncontrolled hypertension and a high cardiovascular risk
(ten-year risk of 30%). The results from this trial showed
that adherence and blood pressure control both improved
but it did not appear to improve long-term cardiovascular
events. This trial is not comparable with ESCAPE in terms
of the population of physicians involved and the nature of
the intervention and patients’ profile.
Conclusions
An easy-to-perform, multifaceted intervention targeting
only GPs increased significantly the proportion of high-
risk hypertensive patients in primary prevention achiev-
ing their recommended therapeutic targets.
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